The breast biopsy market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to limited availability of advanced biopsy systems, reliance on traditional surgical biopsy methods, increasing breast cancer incidence, growing hospital and diagnostic center infrastructure, adoption of ultrasound-guided procedures.
The breast biopsy market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to technological advancements in liquid biopsy and imaging-guided systems, rising awareness of early breast cancer detection, expansion of diagnostic centers and hospitals, increasing integration of ai and data analytics, development of personalized and precision medicine approaches. Major trends in the forecast period include increasing adoption of minimally invasive biopsy procedures, rising use of liquid biopsy techniques, growth in imaging-guided biopsy systems, expansion of breast cancer diagnostic and screening programs, enhanced focus on patient safety and sample accuracy.
The growing prevalence of breast cancer is anticipated to support the expansion of the breast biopsy market going forward. Breast cancer is a malignant tumor that develops in the cells of breast tissue and may spread to other parts of the body if not treated in a timely manner. The increasing prevalence of breast cancer is linked to factors such as longer life expectancy, improved screening and detection techniques, and heightened awareness of the disease. Breast biopsy procedures are used to extract tissue samples from suspicious breast areas to confirm diagnoses and determine cancer characteristics. For example, in October 2025, according to Breastcancer.org, a US-based non-profit organization, an estimated 316,950 women were projected to be diagnosed with invasive breast cancer in 2025, along with approximately 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS). As a result, the rising prevalence of breast cancer is contributing to the expansion of the breast biopsy market.
Leading companies operating in the breast biopsy marker market are focusing on developing innovative products, such as ultrasound-visible site markers, to improve lesion localization and reduce marker displacement during breast biopsy procedures. An ultrasound-visible site marker is an implantable device designed to enhance visualization of biopsy sites during imaging while providing stable localization for future surgical interventions. For example, in August 2023, Mammotome, a US-based provider of breast biopsy and localization technologies, launched HydroMark Plus. This breast biopsy site marker improves lesion visibility under ultrasound, supporting accurate targeting by radiologists and surgeons while minimizing the risk of marker migration during subsequent surgical procedures. As the latest addition to Mammotome’s HydroMark portfolio, HydroMark Plus is engineered for improved procedural reliability and was scheduled for nationwide availability in the US by year-end. Its key features include high ultrasound conspicuity, reduced movement within breast tissue, and compatibility with a wide range of breast imaging and interventional workflows, supporting improved clinical outcomes and procedural confidence.
In May 2024, Lunit Inc., a South Korea-based medical software company, acquired Volpara Health Technologies Ltd. for an undisclosed amount. Through this acquisition, Lunit enhances its portfolio with advanced breast imaging and analytics technologies, strengthening its capabilities in early cancer detection. Volpara Health Technologies Ltd. is a New Zealand-based provider of breast biopsy solutions.
Major companies operating in the breast biopsy market are Siemens Healthineers AG, Fujifilm Holdings Corporation, Becton Dickinson and Company BD, Koninklijke Philips, GE HealthCare Technologies Inc, Hologic Inc, Merit Medical Systems, Argon Medical Devices, Canon Medical Systems Corporation, Devicor Medical Products Inc, Planmed Oy, Menarini-Silicon Biosystems, Seno Medical Instruments Inc, Dilon Technologies Inc, INRAD Inc, Promaxo Inc, Cook Medical LLC, Boston Scientific Corporation, Stryker Corporation, Intact Medical Corporation, Scion Medical Technologies LLC, Galini SRL, Ethicon Surgical Technologies, Encapsule Medical Devices LLC, Cardinal Health Inc, Olympus Corporation, F Hoffmann-La Roche Ltd, Biocept Inc.
North America was the largest region in the breast biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the breast biopsy market by increasing the cost of imported biopsy needles, imaging guidance systems, and liquid biopsy instruments. Segments such as MRI-guided and stereotactic biopsy systems are particularly affected, with major manufacturing regions in Asia-Pacific, including China and India, facing higher import duties. This has led to elevated production and procurement costs, as well as delayed adoption in some regions. On the positive side, tariffs are encouraging local manufacturing, innovation in alternative devices, and investment in domestic production capacities.
The breast biopsy market research report is one of a series of new reports that provides breast biopsy market statistics, including breast biopsy industry global market size, regional shares, competitors with a breast biopsy market share, detailed breast biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast biopsy industry. This breast biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A breast biopsy is a procedure in which a small sample of breast tissue is removed and examined under a microscope to determine whether it is cancerous or benign. It is usually performed when a lump or abnormality is detected through imaging or a physical exam, and it can be done using different techniques such as needle biopsy or surgical biopsy, often guided by imaging methods such as ultrasound or mammography.
The major types of breast biopsy products include biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and others. Biopsy needles are specialized medical instruments designed to collect breast tissue samples for diagnostic evaluation. The image-guided technologies include MRI-guided breast biopsy, ultrasound-guided breast biopsy, mammography-guided stereotactic biopsy, CT-guided biopsy, and others, while the procedures involve needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. These are applied in hospitals, clinics, diagnostic centers, and other settings.
The breast biopsy market consists of revenues earned by providing services such as biopsy procedures, consultations, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast biopsy market also includes sales of biodegradable tissue markers, and semi-automated and fully automated biopsy needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The breast biopsy market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to technological advancements in liquid biopsy and imaging-guided systems, rising awareness of early breast cancer detection, expansion of diagnostic centers and hospitals, increasing integration of ai and data analytics, development of personalized and precision medicine approaches. Major trends in the forecast period include increasing adoption of minimally invasive biopsy procedures, rising use of liquid biopsy techniques, growth in imaging-guided biopsy systems, expansion of breast cancer diagnostic and screening programs, enhanced focus on patient safety and sample accuracy.
The growing prevalence of breast cancer is anticipated to support the expansion of the breast biopsy market going forward. Breast cancer is a malignant tumor that develops in the cells of breast tissue and may spread to other parts of the body if not treated in a timely manner. The increasing prevalence of breast cancer is linked to factors such as longer life expectancy, improved screening and detection techniques, and heightened awareness of the disease. Breast biopsy procedures are used to extract tissue samples from suspicious breast areas to confirm diagnoses and determine cancer characteristics. For example, in October 2025, according to Breastcancer.org, a US-based non-profit organization, an estimated 316,950 women were projected to be diagnosed with invasive breast cancer in 2025, along with approximately 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS). As a result, the rising prevalence of breast cancer is contributing to the expansion of the breast biopsy market.
Leading companies operating in the breast biopsy marker market are focusing on developing innovative products, such as ultrasound-visible site markers, to improve lesion localization and reduce marker displacement during breast biopsy procedures. An ultrasound-visible site marker is an implantable device designed to enhance visualization of biopsy sites during imaging while providing stable localization for future surgical interventions. For example, in August 2023, Mammotome, a US-based provider of breast biopsy and localization technologies, launched HydroMark Plus. This breast biopsy site marker improves lesion visibility under ultrasound, supporting accurate targeting by radiologists and surgeons while minimizing the risk of marker migration during subsequent surgical procedures. As the latest addition to Mammotome’s HydroMark portfolio, HydroMark Plus is engineered for improved procedural reliability and was scheduled for nationwide availability in the US by year-end. Its key features include high ultrasound conspicuity, reduced movement within breast tissue, and compatibility with a wide range of breast imaging and interventional workflows, supporting improved clinical outcomes and procedural confidence.
In May 2024, Lunit Inc., a South Korea-based medical software company, acquired Volpara Health Technologies Ltd. for an undisclosed amount. Through this acquisition, Lunit enhances its portfolio with advanced breast imaging and analytics technologies, strengthening its capabilities in early cancer detection. Volpara Health Technologies Ltd. is a New Zealand-based provider of breast biopsy solutions.
Major companies operating in the breast biopsy market are Siemens Healthineers AG, Fujifilm Holdings Corporation, Becton Dickinson and Company BD, Koninklijke Philips, GE HealthCare Technologies Inc, Hologic Inc, Merit Medical Systems, Argon Medical Devices, Canon Medical Systems Corporation, Devicor Medical Products Inc, Planmed Oy, Menarini-Silicon Biosystems, Seno Medical Instruments Inc, Dilon Technologies Inc, INRAD Inc, Promaxo Inc, Cook Medical LLC, Boston Scientific Corporation, Stryker Corporation, Intact Medical Corporation, Scion Medical Technologies LLC, Galini SRL, Ethicon Surgical Technologies, Encapsule Medical Devices LLC, Cardinal Health Inc, Olympus Corporation, F Hoffmann-La Roche Ltd, Biocept Inc.
North America was the largest region in the breast biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the breast biopsy market by increasing the cost of imported biopsy needles, imaging guidance systems, and liquid biopsy instruments. Segments such as MRI-guided and stereotactic biopsy systems are particularly affected, with major manufacturing regions in Asia-Pacific, including China and India, facing higher import duties. This has led to elevated production and procurement costs, as well as delayed adoption in some regions. On the positive side, tariffs are encouraging local manufacturing, innovation in alternative devices, and investment in domestic production capacities.
The breast biopsy market research report is one of a series of new reports that provides breast biopsy market statistics, including breast biopsy industry global market size, regional shares, competitors with a breast biopsy market share, detailed breast biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast biopsy industry. This breast biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A breast biopsy is a procedure in which a small sample of breast tissue is removed and examined under a microscope to determine whether it is cancerous or benign. It is usually performed when a lump or abnormality is detected through imaging or a physical exam, and it can be done using different techniques such as needle biopsy or surgical biopsy, often guided by imaging methods such as ultrasound or mammography.
The major types of breast biopsy products include biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and others. Biopsy needles are specialized medical instruments designed to collect breast tissue samples for diagnostic evaluation. The image-guided technologies include MRI-guided breast biopsy, ultrasound-guided breast biopsy, mammography-guided stereotactic biopsy, CT-guided biopsy, and others, while the procedures involve needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. These are applied in hospitals, clinics, diagnostic centers, and other settings.
The breast biopsy market consists of revenues earned by providing services such as biopsy procedures, consultations, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast biopsy market also includes sales of biodegradable tissue markers, and semi-automated and fully automated biopsy needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Breast Biopsy Market Characteristics
3. Breast Biopsy Market Supply Chain Analysis
4. Global Breast Biopsy Market Trends and Strategies
5. Breast Biopsy Market Analysis of End Use Industries
7. Global Breast Biopsy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Breast Biopsy Total Addressable Market (TAM) Analysis for the Market
9. Breast Biopsy Market Segmentation
10. Breast Biopsy Market Regional and Country Analysis
11. Asia-Pacific Breast Biopsy Market
12. China Breast Biopsy Market
13. India Breast Biopsy Market
14. Japan Breast Biopsy Market
15. Australia Breast Biopsy Market
16. Indonesia Breast Biopsy Market
17. South Korea Breast Biopsy Market
18. Taiwan Breast Biopsy Market
19. South East Asia Breast Biopsy Market
20. Western Europe Breast Biopsy Market
21. UK Breast Biopsy Market
22. Germany Breast Biopsy Market
23. France Breast Biopsy Market
24. Italy Breast Biopsy Market
25. Spain Breast Biopsy Market
26. Eastern Europe Breast Biopsy Market
27. Russia Breast Biopsy Market
28. North America Breast Biopsy Market
29. USA Breast Biopsy Market
30. Canada Breast Biopsy Market
31. South America Breast Biopsy Market
32. Brazil Breast Biopsy Market
33. Middle East Breast Biopsy Market
34. Africa Breast Biopsy Market
36. Breast Biopsy Market Competitive Landscape and Company Profiles
37. Breast Biopsy Market Other Major and Innovative Companies
40. Breast Biopsy Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Breast Biopsy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses breast biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for breast biopsy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast biopsy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Biopsy Needles; Guidance Systems; Biopsy Tables; Localization Wires; Assay Kits; Liquid Biopsy Instruments; Other Types2) By Image Guided Technology: Magnetic Resonance Imaging (MRI) Guided Breast Biopsy; Ultrasound Guided Breast Biopsy; Mammography Guided Stereotactic Biopsy; Computed Tomography (CT) Guided Biopsy; Other Image Guided Technologies
3) By Procedure: Needle Breast Biopsy; Open Surgical Breast Biopsy; Liquid Breast Biopsy
4) By Application: Hospitals; Clinics; Diagnostic Centers; Other Applications
Subsegments:
1) By Biopsy Needles: Core Biopsy Needles; Fine Needle Aspiration (FNA) Needles; Vacuum-Assisted Biopsy Needles; Automatic Biopsy Needles2) By Guidance Systems: Ultrasound Guidance Systems; MRI Guidance Systems; Stereotactic Guidance Systems; Tomosynthesis Guidance Systems
3) By Biopsy Tables: Adjustable Biopsy Tables; Specialty Biopsy Tables; Imaging-Compatible Biopsy Tables
4) By Localization Wires: Hookwire Localization Devices; Radioguided Localization Wires; Magnetic Seed Localization Systems
5) By Assay Kits: Breast Cancer Assay Kits; Biomarker Detection Kits; Genetic Testing Kits for Breast Cancer
6) By Liquid Biopsy Instruments: Circulating Tumor Cell (CTC) Isolation Devices; Plasma DNA Isolation Kits; Liquid Biopsy Analysis Systems
7) By Other Types: Biopsy Adhesives; Specimen Collection and Transport Devices; Patient Management Systems
Companies Mentioned: Siemens Healthineers AG; Fujifilm Holdings Corporation; Becton Dickinson and Company BD; Koninklijke Philips; GE HealthCare Technologies Inc; Hologic Inc; Merit Medical Systems; Argon Medical Devices; Canon Medical Systems Corporation; Devicor Medical Products Inc; Planmed Oy; Menarini-Silicon Biosystems; Seno Medical Instruments Inc; Dilon Technologies Inc; INRAD Inc; Promaxo Inc; Cook Medical LLC; Boston Scientific Corporation; Stryker Corporation; Intact Medical Corporation; Scion Medical Technologies LLC; Galini SRL; Ethicon Surgical Technologies; Encapsule Medical Devices LLC; Cardinal Health Inc; Olympus Corporation; F Hoffmann-La Roche Ltd; Biocept Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Breast Biopsy market report include:- Siemens Healthineers AG
- Fujifilm Holdings Corporation
- Becton Dickinson and Company BD
- Koninklijke Philips
- GE HealthCare Technologies Inc
- Hologic Inc
- Merit Medical Systems
- Argon Medical Devices
- Canon Medical Systems Corporation
- Devicor Medical Products Inc
- Planmed Oy
- Menarini-Silicon Biosystems
- Seno Medical Instruments Inc
- Dilon Technologies Inc
- INRAD Inc
- Promaxo Inc
- Cook Medical LLC
- Boston Scientific Corporation
- Stryker Corporation
- Intact Medical Corporation
- Scion Medical Technologies LLC
- Galini SRL
- Ethicon Surgical Technologies
- Encapsule Medical Devices LLC
- Cardinal Health Inc
- Olympus Corporation
- F Hoffmann-La Roche Ltd
- Biocept Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.65 Billion |
| Forecasted Market Value ( USD | $ 2.17 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
